Literature DB >> 8810034

Absorption, metabolism and excretion of tamsulosin hydrochloride in man.

Y Soeishi1, H Matsushima, T Watanabe, S Higuchi, K Cornelissen, J Ward.   

Abstract

1. The absorption, excretion and metabolism of tamsulosin hydrochloride (TMS), a potent alpha 1-adrenoceptor blocking agent, were studied in four healthy male subjects after a single oral administration of 14C-TMS at a dose of 0.2 mg. 2. Plasma and blood radioactivity concentrations attained peak levels (Cmax) within 1 h after dosing and then declined biphasically. Mean terminal elimination half-lives were 11.8 h for plasma and 9.1 h for blood. The respective mean area under the radioactivity concentration-time curves (AUC0-infinity) were 122.8 and 57.8 ng equivalents h/ml. 3. Mean plasma Cmax of unchanged TMS was 13.0 ng/ml. Plasma levels of TMS declined biphasically. Mean terminal elimination half-life and AUC0-infinity were 8.4 h and 90.3 ng h/ml. The percentage of unchanged TMS to total radioactivity was 91% for Cmax and 74% for AUC0-infinity indicating small amounts of metabolites in plasma. 4. By 1 week post-dosing, 76.4% of the administered radioactivity was recovered in urine and 21.4% in faeces. The major part of radioactivity excreted in urine was recovered within the first 24 h (62.2% of the dose). 5. Unchanged TMS and 11 metabolites in 0-24-h urine samples were quantified. TMS accounted for 8.7% of the dose. Extensive excretion of the sulphate of the O-deethylated metabolite (M-1-Sul) and o-ethoxyphenoxy acetic acid (AM-1) was seen, accounting for 15.7 and 7.5% of the dose respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8810034     DOI: 10.3109/00498259609046739

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  9 in total

Review 1.  Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.

Authors:  Gabriela Franco-Salinas; Jean J M C H de la Rosette; Martin C Michel
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

2.  Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.

Authors:  Joachim Troost; Shinji Tatami; Yasuhiro Tsuda; Michaela Mattheus; Ludwig Mehlburger; Martina Wein; Martin C Michel
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

3.  Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.

Authors:  Kyoung-Ah Kim; In-Bae Park; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2018-06-13       Impact factor: 2.953

4.  Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.

Authors:  K Taguchi; R F Schäfers; M C Michel
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

5.  The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term.

Authors:  Yigit Akin; Hakan Gulmez; Murat Ucar; Selcuk Yucel
Journal:  Int Urol Nephrol       Date:  2013-01-06       Impact factor: 2.370

Review 6.  Tamsulosin: an update of its role in the management of lower urinary tract symptoms.

Authors:  Katherine A Lyseng-Williamson; Blair Jarvis; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Dutasteride/tamsulosin: in benign prostatic hyperplasia.

Authors:  Gillian M Keating
Journal:  Drugs Aging       Date:  2012-05-01       Impact factor: 3.923

Review 8.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

Authors:  Christopher J Dunn; Anna Matheson; Diana M Faulds
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

9.  Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele.

Authors:  Pureum Kang; Hye-Jung Park; Chang-Keun Cho; Yun Jeong Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2021-11-09       Impact factor: 4.946

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.